Macleods pharma IPO: Mumbai-based Pharma Company Has Filed DRHP With SEBI

Macleods Pharmaceuticals Ltd., one of the leading, vertically integrated, global pharmaceuticals companies in India, which specializes in the development and manufacture of APIs (active pharmaceutical ingredients) and finished dosage pharmaceutical formulations has filed it's Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI).

According to the DRHP of the vertically integrated Macleods Pharma, the initial public offer will consist purely of an offer for sale (OFS) of 60.05 Cr equity shares by promoters. The company to mop-up Rs 5,000 crore through an initial public offering (IPO). In addition, as per the DRHP, a portion of the IPO would be reserved for subscriptions for eligible employees.

ICICI Securities, Kotak Mahindra Capital, Citi, Nomura and Edelweiss Financial Services are the investment banks working on the IPO. Cyril Amarchand Mangaldas and Shardul Amarchand Mangaldas are the legal advisors.

Macleods Pharmaceuticals Ltd.

Mumbai-based Macleods Pharmaceuticals Limited manufactures, develops, and markets a variety of formulations in a variety of therapeutic areas, including anti-infectives, cardiovascular, dermatological, anti-diabetic, and hormone therapy. Through its sales staff, which numbered over 4,900 medical representatives in India as of September 2021, the firm is present in all parts of the country. It also has a global presence in more than 170 countries, including North America, Europe, Africa, Asia, South America, and the Commonwealth of Independent States, in both developed and emerging markets. Macleods is completely owned by its promoter and promoter group, and it has developed organically since its beginning - via internal accruals and without the help of private equity investors.